KSD-101 for EBV-Associated Blood Cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-stage trial tests KSD-101, a new cell therapy, in patients with EBV-related lymphomas (blood cancers) that have come back or stopped responding to previous treatment. The goal is to see if this treatment can help patients who have limited other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of EBV-associated lymphoma (such as diffuse large B-cell lymphoma, Hodgkin's, or NK/T-cell lymphoma) that has returned or stopped responding to prior treatments
- Your lymphoma shows positive EBV (Epstein-Barr virus) markers on a tissue biopsy
- You are in good enough health to tolerate the treatment (ECOG score 0–1, meaning you can carry out most daily activities)
- You have at least one measurable tumor on imaging that is large enough to track
- Your blood counts and organ function (liver, kidney, heart, lungs) meet minimum safe levels, with no recent blood transfusions or growth factor therapy
- You are willing to use non-hormonal contraception for 6 months after your last treatment dose if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies KSD-101 (a vaccine treatment) for people whose blood cancers are linked to EBV and who have not responded or have relapsed after standard treatment. It may help your immune system better control the cancer, especially when other options have already been tried.
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
This trial tests KSD-101, a vaccine designed to help treat or prevent recurrence of blood cancers caused by EBV (Epstein-Barr virus). It may be used for patients whose cancer hasn't responded to standard treatment or as a preventive therapy after treatment.
This trial tests a new treatment called KSD-101 for nasopharyngeal cancer that is linked to the Epstein-Barr virus (EBV) and has not responded to standard therapies. It aims to see if KSD-101 can help people whose cancer has come back or spread.
This trial tests a new therapy called KSD-101 for people with a type of nasopharyngeal cancer linked to the Epstein-Barr virus (EBV). It is for patients whose cancer has returned or spread and who have not responded to standard treatments.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new Relapsed or Refractory EBV-associated Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.